Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 251 to 300 of 309

Type: GuidanceRemove Type: Guidance filter

Guidance and quality standards awaiting development
Title	Type
Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673]	Technology appraisal guidance
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]	Technology appraisal guidance
Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]	Technology appraisal guidance
Talquetamab with pomalidomide or teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6629]	Technology appraisal guidance
Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]	Technology appraisal guidance
Technologies to improve detection of endometrial cancer	Health technology evaluation
Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6628]	Technology appraisal guidance
The Sonata Treatment - Transcervical Radiofrequency Fibroid Ablation using Intrauterine Ultrasound	Medical technologies guidance
Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915]	Technology appraisal guidance
Tildrakizumab for treating active psoriatic arthritis [TSID12218]	Technology appraisal guidance
Timrepigene emparvovec for treating choroideremia [ID3916]	Technology appraisal guidance
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]	Technology appraisal guidance
Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]	Technology appraisal guidance
Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217]	Technology appraisal guidance
Tirzepatide for managing overweight and obesity in people 12 to 17 years [TSID12322]	Technology appraisal guidance
Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease [TSID12347]	Technology appraisal guidance
Tirzepatide for treating type 2 diabetes in people 10 to 17 years [ID6539]	Technology appraisal guidance
Tislelizumab for untreated unresectable hepatocellular carcinoma [TSID10683]	Technology appraisal guidance
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6708]	Technology appraisal guidance
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]	Technology appraisal guidance
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]	Technology appraisal guidance
Tocilizumab for treating systemic sclerosis [ID1396]	Technology appraisal guidance
Topical tapinarof for treating atopic dermatitis in people 2 years and over [ID6713]	Technology appraisal guidance
Topical tapinarof for treating mild to severe plaque psoriasis [ID6712]	Technology appraisal guidance
Tozorakimab for treating exacerbations of chronic obstructive pulmonary disease after optimised inhaled dual or triple therapy [ID6711]	Technology appraisal guidance
Transvaginal Ultrasound-Guided Radiofrequency Ablation (RFA) for Uterine Fibroids	Interventional procedures guidance
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]	Technology appraisal guidance
Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511]	Technology appraisal guidance
Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603]	Technology appraisal guidance
Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]	Technology appraisal guidance
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]	Technology appraisal guidance
Treprostinil diethanolamine for treating pulmonary arterial hypertension [TSID11772]	Technology appraisal guidance
Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]	Technology appraisal guidance
Troriluzole for spinocerebellar ataxia [ID6456]	Technology appraisal guidance
Tucatinib with pertuzumab and trastuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]	Technology appraisal guidance
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [TSID11781]	Technology appraisal guidance
Upadacitinib for treating moderate to severe hidradenitis suppurativa in people 12 years and over [ID6666]	Technology appraisal guidance
UX111 for treating mucopolysaccharidosis type IIIA [ID6540]	Technology appraisal guidance
V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]	Technology appraisal guidance
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]	Technology appraisal guidance
Vamikibart for treating uveitic macular oedema [ID6671]	Technology appraisal guidance
Veligrotug for treating thyroid eye disease [ID6636]	Technology appraisal guidance
Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]	Technology appraisal guidance
Vilobelimab for treating COVID 19 [TSID11815]	Technology appraisal guidance
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]	Technology appraisal guidance
WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]	Technology appraisal guidance
Xanomeline tartrate–trospium chloride for treating schizophrenia [TSID12311]	Technology appraisal guidance
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902]	Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765]	Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable [TSID10477]	Technology appraisal guidance

Results per page

10
25
50
All